1-4 of 4
Tiffany Y. Chang, MD
Close
Sort by
Journal Articles

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

Anna Kiialainen, PhD, Markus Niggli, PhD, Christine L. Kempton, MD MSc, Giancarlo Castaman, MD, Tiffany Y. Chang, MD MAS, Ido Paz-Priel, MD, Joanne I Adamkewicz, PhD, Gallia G. Levy, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 626.
https://doi.org/10.1182/blood-2019-123689
Published: 2019
Journal Articles

Estimating the Risk of Myocardial Infarction in Persons with Hemophilia A Using a Machine-Learning Approach with US Claims Data

Imi Faghmous, MPH, Carlos Flores, MPH, Kati Sarouei, MD, Tiffany Y. Chang, MD MAS, Anisha M. Patel, PhD, Cami S. Sima, MD, Peter Kuebler, PharmD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1133.
https://doi.org/10.1182/blood-2019-123761
Published: 2019
Journal Articles

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

Michael Callaghan, MD, Benjamin Trzaskoma, MS, Richard H. Ko, MD, Lucy Lee, PharmD, Anisha M. Patel, PhD, Eunice Tzeng, PharmD, Michelle Lynn Shah, PharmD, Tiffany Y. Chang, MD MAS, Markus Niggli, PhD, Christophe Dhalluin, PhD, Johnny Mahlangu, MMed, FCPath
Journal: Blood
Blood (2019) 134 (Supplement_1): 2395.
https://doi.org/10.1182/blood-2019-123654
Published: 2019
Journal Articles

MEK Inhibition Modulates the Growth of Nf1 mutant Hematopoietic Cells and Induces Clinical Improvement in a Murine Model of Juvenile Myelomonocytic Leukemia (JMML)

Tiffany Y. Chang, MD, Kimberly Krisman, BA, Emily Rose Harding-Theobald, BA, Benjamin S. Braun, MD, PhD, Kevin M. Shannon, MD
Journal: Blood
Blood (2011) 118 (21): 797.
https://doi.org/10.1182/blood.V118.21.797.797
Published: 2011